Elephant Continues to Expand
WALNUT CREEK, Calif Elephant Pharm has opened its fourth store in the city of Walnut Creek, Calif., a 12,000-square-foot location on South California Blvd. The store occupies part of a building that was an Albertson’s supermarket and is now home to a Trader Joe’s.
The independent drug store chain – formerly known as Elephant Pharmacy – says the store offers a mix of both herbal and conventional medications and will carry a large selection of baby products and stationary but no food.
CEO Kathi Lentzsch said the store also has a different look than its other locations with mix of ‘upbeat but warm’ blues and greens.
“It’s kind of unusual,” said Lentzsch. “I don’t think most drug stores pay attention to the colors in their stores.” She added that Elephant Pharm chose Walnut Creek as a store site because of is affluent and health-conscious demographic.
Roche to sue Teva over patent of Boniva
BASEL, Switzerland Swiss pharmaceutical company Roche Holding has filed suit against generic pharmaceutical maker Teva over Roche’s patented osteoporosis treatment, the company said Tuesday.
Roche filed a complaint at a New Jersey district court to prevent Teva from selling their generic version of Boniva, the company’s spokeswoman said.
Sales of Boniva for the first six months of the year totaled $314 million. Recently, Roche’s rival Novartis filed for an injunction against the generic pharmaceutical maker to halt the creation and production of its Famvir herpes treatment. Novartis was denied the injunction but was granted one by the U.S. District Court of Appeals a few days later.
King Pharma announces intention to fight Actavis’ generic Avinza
BRISTOL, Tenn. King Pharmaceuticals has recently learned that Actavis has filed paperwork with the Food and Drug Administration to make a generic version of their pain medication Avinza (morphine sulfate).
King “intends to vigorously enforce the patent on Avinza” by starting legal procedures that will most likely ending up with the two companies meeting in federal court. King spokesman James Green said, “The business of generic manufacturers is to challenge as many patents as possible, hoping to win a few.”
At the beginning of the year King acquired all the rights to Avinza from Ligand Pharmaceuticals and has seen revenues of $9 million and $35 million in the first and second quarters of 2007.
Avinza’s patent does not end until Nov. 25, 2017.